Citi opened a “90-day negative Catalyst Watch” on shares of Atara Biotherapeutics and keeps a Sell rating on the shares with a $1.40 price target. Data from the Phase 2 EMBOLD study evaluating ATA188 in progressive multiple sclerosis are expected in early November, the analyst tells investors in a research note. The firm views EMBOLD as “highly risky” and believes the study is unlikely to achieve statistical significance on the primary endpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATRA:
- Poseida Therapeutics names Kristin Yarema, Ph.D as CEO, effective Jan 1, 2024
- Atara stock could get ‘very loud very fast,’ says Mizuho
- Biotech Alert: Searches spiking for these stocks today
- Atara Biotherapeutics to submit Tab-cel BLA after FDA compatibility agreement
- Atara Biotherapeutics participates in a conference call with JPMorgan